These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30764026)

  • 1. Overcoming challenges in Type 2 diabetes management to improve patient outcomes.
    Brown MT; LeRoith D
    Expert Rev Endocrinol Metab; 2010 Sep; 5(5):741-751. PubMed ID: 30764026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
    Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.
    Goldenberg RM
    Can J Diabetes; 2011 Dec; 35(5):518-27. PubMed ID: 24854977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action.
    Schernthaner-Reiter MH; Schernthaner G
    Expert Rev Endocrinol Metab; 2016 May; 11(3):281-296. PubMed ID: 30058933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.
    Nadeau DA
    Postgrad Med; 2010 May; 122(3):7-15. PubMed ID: 20463409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin in type 2 diabetes.
    Billiones R
    Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
    Kheirandish M; Mahboobi H; Yazdanparast M; Kamal MA
    Curr Drug Metab; 2017; 18(2):157-162. PubMed ID: 28093996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A report from the 47th European Association for the Study of Diabetes annual meeting (September 12-16, 2011 - Lisbon, Portugal).
    Rabasseda X
    Drugs Today (Barc); 2011 Dec; 47(12):923-34. PubMed ID: 22348917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J; Zinman B
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):98-107. PubMed ID: 17940427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.